U.S. markets close in 12 minutes

FUJIFILM Holdings Corporation (FUJIY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
58.11+0.02 (+0.03%)
As of 3:31PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close58.09
Open58.25
Bid0.00 x 0
Ask0.00 x 0
Day's Range58.11 - 58.52
52 Week Range36.60 - 63.09
Volume8,144
Avg. Volume16,421
Market Cap23.158B
Beta (5Y Monthly)0.20
PE Ratio (TTM)20.50
EPS (TTM)2.84
Earnings DateN/A
Forward Dividend & Yield0.91 (1.56%)
Ex-Dividend DateSep 28, 2020
1y Target Est71.43
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Fujifilm's Avigan shows no significant benefit on COVID-19 mortality - study
    Reuters

    Fujifilm's Avigan shows no significant benefit on COVID-19 mortality - study

    A study of global trials of Fujifilm Holdings Corp's antiviral drug Avigan suggests it has little benefit for COVID-19 patients once their symptoms become serious. The meta-analysis of nine clinical trials showed the drug, known generically as favipiravir, helped patients early on in their hospitalisation, according to the preprint of a study posted Wednesday on the medical website medRxiv. "We should consider that perhaps the use of antivirals once the patient has symptoms is too late and this would explain their low efficacy in the clinical setting," wrote the authors, led by Soheil Hassanipoura of Iran's Guilan University of Medical Sciences.

  • Xerox Looks Past Q4 For Stronger 2021
    Benzinga

    Xerox Looks Past Q4 For Stronger 2021

    Xerox Holdings Corp. (NYSE: XRX) ended its fourth quarter with a weaker financial picture and the expressed hope for a more solid 2021. What Happened: The Norwalk, Connecticut-based company reported $77 million in fourth-quarter net profits Tuesday, a far cry from the $818 million it reported one year earlier. The quarter's $1.93 billion in revenue represented a 21% year-over-year tumble, while the earnings of 58 cents per share were 56% lower year-over-year. The fourth quarter also saw the company shedding 750 positions worldwide, which gave Xerox a total global workforce reduction of 2,300 for the year. Why It's Important: While Xerox's earnings report attributed much of its problems to the ongoing COVID-19 pandemic, which saw the rise of a remote workforce that did not require its office-centric technologies while working from home, many of the company's problems preceded the health crisis. At the start of 2020, Xerox had managed to reach an amicable resolution with Japan's Fujifilm Holdings (Pink: FUJIY) following the contentious and litigious cancellation of their planned merger. But no sooner was Fujifilm Holdings in Xerox's rear-view mirror than it began to chase after HP Inc. (NYSE: HPQ) in a hostile takeover that consisted of veiled public threats, brash displays of financial prowess and even the promise of free dinners for HP shareholders at a ritzy restaurant in the pricey New York suburb of Greenwich, Connecticut. HP greeted the effort with a mix of bafflement and indifference, and Xerox abruptly halted its plans when the COVID-19 pandemic took root, leaving it with a public relations disaster. View more earnings on XRX As the year progressed, Xerox continued to have an optics problem. Activist investor Carl Icahn, Xerox's largest shareholder, became the center of media attention by increasing his ownership stake with a robust acquisition of shares. Icahn's cantankerous behavior was also responsible for ending the Fujifilm Holdings merger and encouraging the doomed pursuit of HP, which made his share-buying spree even more curious. Also giving Xerox black eyes were a pair of widely reported cybersecurity breaches last fall, which was rather embarrassing because Xerox was trying to position itself as a cybersecurity expert. What's Next: Xerox Vice Chairman and CEO John Visentin used the fourth- quarter earnings call to accentuate the positive while admitting a return to growth was not in the cards for this first quarter of this year. In 2021, Xerox expects revenue of at least $7.2 billion in constant currency; operating cash flow from continuing operations to total at least $600 million; and free cash flow of at least $500 million, the CEO said. "We believe this is achievable even in the unlikely scenario businesses don't start reopening in a meaningful way in the first half. The benefit of a solid strategy is it's flexible in its application, yet strong in its foundation," he said. Visentin also promised that 2021 will see the company "adding workflow automation, machine learning, artificial intelligence and remote services to make our clients [and] employees more efficient while maintaining security." Xerox's "strong cash position provides flexibility to explore a wide range of M&A opportunities," Visentin said. Without mentioning Fujifilm Holdings or HP, Visentin held out the hope that the third time would be the charm for growing the company by uniting with another. See more from BenzingaClick here for options trades from BenzingaWill Godiva's Retail Exit Spark New Chocolate War?Chief Diversity Officers Take On New Visibility, Challenges© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Reuters

    Fujifilm says will invest $2 bln in new large-scale cell culture production site in U.S.

    Fujifilm Holdings Corp said on Wednesday it will invest $2 billion to establish new large-scale cell culture production site in the United States. The new plant will help accelerate growth of the Japanese company's biopharmaceutical contract development and manufacturing business (CDMO), Fujifilm said in a release.